Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are extensively used in treating diabetes and obesity, yet little is known about the long-term ocular effects of systemic prolonged exposure.Objective To evaluate the risk of developing neovascular age-related macular degeneration (nAMD) associated with the use of GLP-1 RAs in patients with diabetes.Design, Setting, and Participants This population-based,… Continue reading #Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related #Macular #Degeneration
Tag: Semaglutide
Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated Steatohepatitis
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH).MethodsIn this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or… Continue reading Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated Steatohepatitis
Once-Weekly #Semaglutide in Persons with #Obesity and #Knee Osteoarthritis
BackgroundWeight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well studied.MethodsWe conducted a 68-week, double-blind, randomized, placebo-controlled trial at 61 sites in 11 countries. Participants with obesity (a body-mass index… Continue reading Once-Weekly #Semaglutide in Persons with #Obesity and #Knee Osteoarthritis
Associations of #semaglutide with first-time diagnosis of #Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US
INTRODUCTIONEmerging preclinical evidence suggests that semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) for type 2 diabetes mellitus (T2DM) and obesity, protects against neurodegeneration and neuroinflammation. However, real-world evidence for its ability to protect against Alzheimer's disease (AD) is lacking.METHODSWe conducted emulation target trials based on a nationwide database of electronic health records (EHRs) of 116… Continue reading Associations of #semaglutide with first-time diagnosis of #Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US
Metabolic effects of very-low calorie #diet, #Semaglutide, or combination of the two, in individuals with type 2 #diabetes mellitus
Background & aimsVery-low calorie diets (VLCD) and the glucagon-like peptide-1 receptor agonist (GLP1RA) Semaglutide induce significant weight loss and improve glycaemic control in individuals with type 2 diabetes (T2D). This pilot study was conducted to explore the comparative short-term effects of these interventions individually, and in combination, on weight, body composition and metabolic outcomes.MethodsThirty individuals… Continue reading Metabolic effects of very-low calorie #diet, #Semaglutide, or combination of the two, in individuals with type 2 #diabetes mellitus
#Semaglutide in Early Type 1 #Diabetes
In this small case series, semaglutide after the diagnosis of type 1 diabetes led to elimination of prandial insulin in all patients and basal insulin in most, along with improved glycemic control. https://www.nejm.org/doi/full/10.1056/NEJMc2302677
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
BackgroundGlucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD). However, the probability of low semaglutide doses, an agonist with higher potency and affinity for GLP-1R, to attenuate alcohol-related responses in rodents and the underlying neuronal mechanisms is unknown.MethodsIn the intermittent access model,… Continue reading Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
BackgroundPharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for the benefits and harms of weight-lowering drugs. MethodsThis systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled… Continue reading Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
#Semaglutide 2·4 mg once a week in adults with #overweight or #obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight or obesity, and type 2 diabetes. Methods This double-blind, double-dummy, phase 3, superiority study enrolled adults with… Continue reading #Semaglutide 2·4 mg once a week in adults with #overweight or #obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
2 Medical News 